Can-Fite BioPharma Ltd.
CANFHealthcare|Biotechnology|IL
$1.62
+0.02 (+1.25%)
Tangible Book / Share
$2.62
Cash / Share
$3.80
Clinical Trials (22)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05201404 Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | Hepatocellular Carcinoma, Cirrhosis | P3 | Recruiting | 471 | RCT, Double-blind | Namodenoson, Placebo |
| NCT06387342 Namodenoson Treatment of Advanced Pancreatic Cancer | Pancreatic Adenocarcinoma, Pancreatic Cancer | P2 | Recruiting | 20 | Open-label | Namodenoson 25mg |
| NCT01235234 Trial of CF101 to Treat Patients With Dry Eye Disease | Keratoconjunctivitis Sicca | P3 | Completed | 236 | RCT, Double-blind | CF101 |
| NCT02647762 CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Terminated | 244 | RCT, Double-blind | CF101 1 mg, CF101 2 mg, Placebo, MTX |
| NCT03168256 CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis | Plaque Psoriasis | P3 | Completed | 528 | RCT, Double-blind | CF101 2mg, CF101 3mg, Apremilast 30mg, Placebo Oral Tablet |
| NCT01265667 Trial of CF101 to Treat Patients With Psoriasis | Plaque Psoriasis | P2P3 | Completed | 293 | RCT, Double-blind | CF101, Placebo |
| NCT06643260 A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy | Plaque Psoriasis | P3 | Not Yet Recruiting | 705 | RCT, Double-blind | piclidenoson, Placebo |
| NCT04697810 Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) | NASH - Nonalcoholic Steatohepatitis | P2 | Unknown | 114 | RCT, Double-blind | Namodenoson, Placebo |
| NCT01033422 Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure | Ocular Hypertension, Glaucoma | P2 | Completed | 89 | RCT, Double-blind | CF101, Placebo for |
| NCT01905124 Safety &Efficacy of CF101 to Subjects With Uveitis | Uveitis, Posterior, Uveitis, Intermediate | P2 | Withdrawn | — | RCT, Double-blind | CF101, Placebo |
| NCT00790673 A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 | Chronic Hepatitis C | P1P2 | Completed | 32 | RCT, Double-blind | CF 102, Placebo |
| NCT00837291 A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee | Osteoarthritis of the Knee | P2 | Withdrawn | — | RCT, Double-blind | CF101, Placebo |
| NCT00790218 A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | P1P2 | Completed | 19 | Open-label | CF102 |
| NCT07410455 An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome | Lowe Syndrome | P2 | Not Yet Recruiting | 5 | Open-label | Piclidenoson |
| NCT00428974 Safety and Efficacy Study of CF101 to Treat Psoriasis | Plaque Psoriasis | P2 | Completed | 76 | RCT, Double-blind | CF101 1mg, CF101 2mg, CF101 4mg, Placebo |
| NCT00556894 Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | P2 | Completed | 253 | RCT, Double-blind | CF101, Placebo |
| NCT02128958 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | P2 | Completed | 78 | RCT, Double-blind | CF102, Placebo |
| NCT02927314 A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis (NASH) | P2 | Completed | 60 | RCT, Double-blind | CF102, Placebo |
| NCT01034306 Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 79 | RCT, Double-blind | CF101, Placebo control |
| NCT00280917 Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | P2 | Completed | 254 | Double-blind | CF101 |
| NCT00349466 Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca | Keratoconjunctivitis Sicca | P2 | Completed | 80 | RCT, Double-blind | CF101, Placebo |
| NCT04333472 Piclidenoson for Treatment of COVID-19 | COVID-19, Coronavirus Infection | P2 | Completed | 6 | RCT, Double-blind | Piclidenoson, Placebo |